Trials / Not Yet Recruiting
Not Yet RecruitingNCT06926998
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
An Open-Label, Multicenter Phase Ib/ll Clinical Study Evaluating the Safety and Efficacy of 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9MW2821+other anticancer therapy | Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol |
Timeline
- Start date
- 2025-04-15
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2025-04-15
- Last updated
- 2025-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06926998. Inclusion in this directory is not an endorsement.